First Hawaiian Bank Has $4.10 Million Stake in Boston Scientific Co. (NYSE:BSX)

First Hawaiian Bank lowered its holdings in Boston Scientific Co. (NYSE:BSX) by 15.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,847 shares of the medical equipment provider’s stock after selling 8,638 shares during the period. First Hawaiian Bank’s holdings in Boston Scientific were worth $4,095,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Collective Family Office LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $209,000. Bank of New Hampshire raised its holdings in Boston Scientific by 14.8% in the 4th quarter. Bank of New Hampshire now owns 2,565 shares of the medical equipment provider’s stock valued at $229,000 after acquiring an additional 330 shares in the last quarter. CWA Asset Management Group LLC lifted its position in shares of Boston Scientific by 4.2% during the 4th quarter. CWA Asset Management Group LLC now owns 8,281 shares of the medical equipment provider’s stock valued at $740,000 after acquiring an additional 336 shares during the period. Nordea Investment Management AB grew its holdings in shares of Boston Scientific by 6.7% during the 4th quarter. Nordea Investment Management AB now owns 119,535 shares of the medical equipment provider’s stock worth $10,713,000 after purchasing an additional 7,540 shares in the last quarter. Finally, Everence Capital Management Inc. grew its stake in Boston Scientific by 15.8% during the fourth quarter. Everence Capital Management Inc. now owns 49,660 shares of the medical equipment provider’s stock worth $4,436,000 after buying an additional 6,770 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BSX. JPMorgan Chase & Co. upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Bank of America raised their target price on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Canaccord Genuity Group boosted their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Wells Fargo & Company raised their price objective on Boston Scientific from $98.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Evercore ISI increased their target price on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Four research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares in the company, valued at $2,660,580.24. This represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,989 shares of company stock valued at $2,702,261 in the last ninety days. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Up 4.2 %

Shares of BSX traded up $3.89 during mid-day trading on Wednesday, reaching $95.88. 10,743,923 shares of the company were exchanged, compared to its average volume of 5,468,137. The business has a 50 day simple moving average of $89.25 and a two-hundred day simple moving average of $83.50. Boston Scientific Co. has a 52 week low of $58.09 and a 52 week high of $97.13. The stock has a market capitalization of $141.31 billion, a PE ratio of 79.24, a PEG ratio of 2.67 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the company earned $0.50 EPS. The company’s revenue for the quarter was up 19.3% on a year-over-year basis. On average, analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.